Politics Rachel Cohrs STAT Plus: Biden administration to fine manufacturers of 27 medicines for price hikes
Politics John Wilkerson STAT Plus: PhRMA chief dings health insurers over drug prices at their own conference
Business Bob Herman and Casey Ross STAT Plus: Buyer’s remorse: How a Medicare Advantage business is strangling one of its first funders
Politics Joanne Silberner STAT Plus: Medicare will take R&D costs, effectiveness into account when it negotiates drug prices. But studies show that doesn’t affect prices
Politics Rachel Cohrs STAT Plus: An unlikely new 340B alliance emerges between PhRMA and community health centers
Politics John Wilkerson STAT Plus: Medicare chief on the new drug price negotiation program’s operations, hiring, and timelines
First Opinion Cynthia A. Fisher New analysis: CMS vastly overestimates hospital price transparency efforts
First Opinion David Mitchell STAT Plus: Another pharma industry flip-flop: Claims about the IRA’s effect on small-molecule versus biologic drugs
Hospitals John Wilkerson STAT Plus: Here’s another sign the Biden administration is taking a harsher stance on hospital consolidation
Politics Sarah Owermohle STAT Plus: Doctors’ top lobbyist in Washington on Medicare money, burnout, and private equity
Politics Rachel Cohrs and John Wilkerson STAT Plus: Biden administration pitches 3 big new drug pricing reform experiments
Politics Rachel Cohrs STAT Plus: Medicare advisers suggest tweaks to coverage process for Alzheimer’s drugs
Politics John Wilkerson STAT Plus: Generics companies fought to stop the new drug pricing law. But they may end up benefiting
First Opinion MacKay Jimeson State of the Union highlights America’s awkward conversation on financing the development of new medicines
Insurance Bob Herman and Tara Bannow STAT Plus: CVS’ Oak Street Health acquisition continues the industry’s provider obsession
Biotech Rachel Cohrs STAT Plus: How one biotech investor is changing his calculus now that Medicare can negotiate drug prices
Business Bob Herman STAT Plus: Biden administration floats major 2024 pay cut for Medicare Advantage plans
Insurance Bob Herman and Tara Bannow STAT Plus: Medicare Advantage insurers will score $2 billion gift thanks to limited audits
Politics John Wilkerson STAT Plus: Medicare may test policy of paying less for accelerated approval drugs
Insurance Bob Herman and Tara Bannow STAT Plus: Medicare Advantage insurers to repay billions under final federal audit rule
Insurance Bob Herman STAT Plus: ‘Everybody has blood on their hands’: A decade-long battle over Medicare Advantage audits is coming to a head
Exclusive Sarah Owermohle STAT Plus: HHS’ Becerra on enrolling in Medicare, annual Covid vaccines, and seniors’ mental health
Politics Rachel Cohrs STAT Plus: The unexpected alliance lobbying for Medicare to pay for new obesity drugs